Pharma

Your Article Summary

See Latest Articles

New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents
Cell Therapeutics, 12/02/09

Cell Therapeutics, Inc. announced that its new class of platinum–based anti–tumor compounds, termed bis–platinates, demonstrated a stronger anti–tumor potency and activity compared to currently available platinum–based compounds as well as the ability to overcome cisplatin–resistance in cancer cell lines. The results were presented in a paper titled "Novel Bis–platinum Complexes Endowed with an Improved Pharmacological Profile," by Laura Gatti et al. that was published in the online edition of the journal Molecular Pharmaceutics.

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

Bayer MaterialScience develops drug-releasing coatings for medical applications
BayNews International, 03/19/10

First Publication of Data from Pivotal Clinical Trial for Medtronic Deep Brain Stimulation Therapy for Epilepsy Published Today in Epilepsia
Medtronic, 03/19/10

CEL-SCI Completes Validation Of Manufacturing Facility Allowing It To Commence Manufacturing Of Multikine
CEL-SCI, 03/19/10

 See all of Research & Development